DSGN
Design Therapeutics Inc
$
4.280
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.3382
Open
4.140
VWAP
4.14
Vol
76.92K
Mkt Cap
243.74M
Low
3.970
Amount
318.27K
EV/EBITDA(TTM)
--
Total Shares
56.50M
EV
9.10M
EV/OCF(TTM)
--
P/S(TTM)
--
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
--
--
-0.343
+43.05%
--
--
-0.340
+47.83%
--
--
-0.330
+57.14%
Estimates Revision
Stock Price
Go Up
+21.59%
In Past 3 Month
3 Analyst Rating
98.60% Upside
Wall Street analysts forecast DSGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DSGN is 8.50 USD with a low forecast of 5.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
98.60% Upside
Current: 4.280
Low
5.00
Averages
8.50
High
12.00
98.60% Upside
Current: 4.280
Low
5.00
Averages
8.50
High
12.00
The End
See All Ratings
No Data
Valuation Metrics
The current forward P/E ratio for Design Therapeutics Inc (DSGN.O) is -3.24, compared to its 5-year average forward P/E of -9.60. For a more detailed relative valuation and DCF analysis to assess Design Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-9.60
Current PE
-3.24
Overvalued PE
-0.63
Undervalued PE
-18.58
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-4.63
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.97
Undervalued EV/EBITDA
-12.23
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q2
N/A
Total Revenue
FY2025Q2
YoY :
+43.38%
-21.57M
Operating Profit
FY2025Q2
YoY :
-100.00%
N/A
Net Income after Tax
FY2025Q2
YoY :
+61.90%
-0.34
EPS - Diluted
FY2025Q2
YoY :
+27.20%
-14.53M
Free Cash Flow
FY2025Q2
N/A
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
23.9K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 108.37% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
814.9K
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
1
904.0K
Volume
Months
6-9
2
433.9K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
23.9K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
DSGN News & Events
Events Timeline
2025-08-07 (ET)
2025-08-07
16:15:50
Design Therapeutics reports Q2 EPS (34c), consensus (33c)
2025-06-04 (ET)
2025-06-04
07:08:26
Design Therapeutics announces first FA patient dosed in RESTORE-FA trial
2025-05-06 (ET)
2025-05-06
13:07:28
Controversial doctor Vinay Prasad named CBER director, STAT reports
Sign Up For More Events
Sign Up For More Events
News
9.0
04-21Yahoo FinanceDesign Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
5.0
04-16GlobenewswireBright Peak Therapeutics Appoints John Schmid to its Board of Directors
9.5
03-10NewsfilterDesign Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
Sign Up For More News
People Also Watch
FPH
Five Point Holdings LLC
5.360
USD
-0.19%
IMMP
Immutep Ltd
1.790
USD
-1.10%
DOMO
Domo Inc
15.970
USD
-2.26%
AQST
Aquestive Therapeutics Inc
3.900
USD
-0.76%
BRBS
Blue Ridge Bankshares Inc
3.600
USD
-0.28%
RGP
Resources Connection Inc
4.600
USD
-0.86%
ARQ
Arq Inc
6.620
USD
+6.95%
RZLT
Rezolute Inc
5.810
USD
+4.31%
SMTI
Sanara Medtech Inc
24.800
USD
+1.81%
AVIR
Atea Pharmaceuticals Inc
3.380
USD
-2.31%
FAQ
What is Design Therapeutics Inc (DSGN) stock price today?
The current price of DSGN is 4.28 USD — it has increased 7.81 % in the last trading day.
What is Design Therapeutics Inc (DSGN)'s business?
What is the price predicton of DSGN Stock?
What is Design Therapeutics Inc (DSGN)'s revenue for the last quarter?
What is Design Therapeutics Inc (DSGN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Design Therapeutics Inc (DSGN)'s fundamentals?
How many employees does Design Therapeutics Inc (DSGN). have?